Advanced NanoTherapies obtains over $31 million in Series B funding for dual-drug nanoparticle-coated balloon therapy
Advanced NanoTherapies has secured more than $31 million in a fully subscribed Series B round led by an unnamed strategic investor and S3 Ventures. The financing will support the company's IDE exemption approval, coronary clinical development, and expansion of below-the-knee (BTK) applications for its dual-drug nanoparticle-coated balloon technology.
Topics: biotech clinical_trials medical_devices